| 发明名称 |
Novel Administration Regime |
| 摘要 |
The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c). |
| 申请公布号 |
US2016058840(A1) |
申请公布日期 |
2016.03.03 |
| 申请号 |
US201414888118 |
申请日期 |
2014.04.30 |
| 申请人 |
NOVO NORDISK A/S |
发明人 |
Johansen Thue;Francisco Ann Marie Ocampo;Christensen Torsten;Kongsoe Jens Harald;Ahlgreen Trine |
| 分类号 |
A61K38/28;A61K38/26;A61K45/06 |
主分类号 |
A61K38/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A long-acting or ultra-long-acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps:
(a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood or plasma glucose measurement from said individual in need of treatment; (c) using the single fasting blood or plasma glucose measurement to determine the insulin dose to be administered; and (d) administering said insulin to the individual at the dose determined in step (c). |
| 地址 |
Bagsvaerd DK |
